Physician profile
Renee Mathis
NPI 1952919102
$4,966.35
in general payments reported to CMS, 2019-2025
18 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $151 · 2023: $1,667 · 2024: $1,814 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,754 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,753.93 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $876.46 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $694.33 | 2023-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $647.34 | 2022-2025 | |
| Alkermes, INC. | $556.99 | 2023-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $518.37 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $473.48 | 2024-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $220.91 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $188.99 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $149.04 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $142.82 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $118.89 | 2023 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $101.21 | 2023 | Austedo |
| Alexion Pharmaceuticals, INC. | $99.99 | 2023 | |
| Tris Pharma INC | $50.22 | 2023-2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $42.89 | 2023-2024 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $33.67 | 2023-2025 | Azstarys |
| Almatica Pharma LLC | $30.24 | 2024 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $20.51 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.